Shear‐Responsive Drug Delivery Systems in Medical Devices: Focus on Thrombosis and Bleeding
Source abstract
Abstract
Abstract Cardiovascular disease is the leading cause of death worldwide. Blood‐contacting medical devices provide critical support for patients with severe respiratory and/or cardiac failure. High shear stress zones and non‐biocompatible circuit can increase the risk of thrombus formation in patients. These thrombi restrict blood flow through the circuits and travel to the lungs and brain, creating significant consequences. Antithrombotic drugs are used to lower this risk, but they also raise the incidence of bleeding problems. This article explores the delicate balance between thrombosis and bleeding in medical devices by examining platelet activation and thrombosis formation under shear stress. The feasibility of a shear‐responsive nanomedicine‐based drug delivery system has been explored as a potential approach for targeted administration of antithrombotic medications to lower systemic drug levels and reduce the bleeding risk. Furthermore, the lack of in vitro platforms to investigate the biological behavior of antithrombotic nanoparticles is impeding their clinical translation. As a result, microfluidic technology offers a platform for investigating nanoparticle behavior in vitro and linking it to their performance in vivo. Finally, the challenges and factors that affect the functionality, stability, and circulation time of liposomal drugs are investigated to improve their efficacy for targeted drug administration in medical devices.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Mechanical Circulatory Support Devices · Blood properties and coagulation · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Centre for Blood Diseases, Central Clinical School Monash University Melbourne Victoria 3004 Australia
Cardiorespiratory Engineering and Technology Laboratory Department of Mechanical and Aerospace Engineering Monash University Clayton Victoria 3800 Australia
Funding
National Health and Medical Research Council · National Heart Foundation of Australia
References (100+)
Show source-provided references
1. 10.1089/ten.teb.2021.014810.1089/ten.teb.2021.0148 ↗
2. 10.1002/adfm.20180824710.1002/adfm.201808247 ↗
3. 10.3390/membranes1105031310.3390/membranes11050313 ↗
4. Bhat A. G. · Case Rep Crit Care · 2019 · 2019
5. 10.1177/026765911774536910.1177/0267659117745369 ↗
6. 10.1097/CCM.000000000000412910.1097/CCM.0000000000004129 ↗
7. 10.1111/aor.1405810.1111/aor.14058 ↗
8. 10.1186/s13613-017-0275-410.1186/s13613-017-0275-4 ↗
9. Zangrillo A. · Crit Care Resusc · 2013 · 15 · 172
10. 10.1097/MAT.000000000000047510.1097/MAT.0000000000000475 ↗
11. 10.1016/j.thromres.2022.02.01510.1016/j.thromres.2022.02.015 ↗
12. 10.1002/anbr.20220010110.1002/anbr.202200101 ↗
13. 10.3324/haematol.2020.25076110.3324/haematol.2020.250761 ↗
14. 10.1002/adfm.20221417910.1002/adfm.202214179 ↗
15. 10.1182/blood.202000720910.1182/blood.2020007209 ↗
16. 10.1002/adfm.20190628310.1002/adfm.201906283 ↗
17. 10.1002/adfm.20210825610.1002/adfm.202108256 ↗
18. 10.1016/j.actbio.2019.06.02110.1016/j.actbio.2019.06.021 ↗
19. 10.1002/adhm.20210098810.1002/adhm.202100988 ↗
20. 10.1016/j.biomaterials.2004.01.02310.1016/j.biomaterials.2004.01.023 ↗
21. 10.3389/fbioe.2020.0012310.3389/fbioe.2020.00123 ↗
22. 10.1016/S0049-3848(10)70151-110.1016/S0049-3848(10)70151-1 ↗
23. 10.1111/jth.1221710.1111/jth.12217 ↗
24. 10.1016/j.blre.2020.10073310.1016/j.blre.2020.100733 ↗
25. 10.1161/01.ATV.0000222982.55731.f110.1161/01.ATV.0000222982.55731.f1 ↗
26. 10.1016/j.mtbio.2022.10030310.1016/j.mtbio.2022.100303 ↗
27. 10.1016/j.colsurfb.2020.11111810.1016/j.colsurfb.2020.111118 ↗
28. 10.1002/rth2.1210710.1002/rth2.12107 ↗
29. 10.1097/MAT.000000000000149310.1097/MAT.0000000000001493 ↗
30. 10.1016/S0021-9150(01)00433-610.1016/S0021-9150(01)00433-6 ↗
31. 10.1016/j.jbiomech.2021.11089810.1016/j.jbiomech.2021.110898 ↗
32. 10.3389/fcvm.2019.0014110.3389/fcvm.2019.00141 ↗
33. 10.3389/fped.2021.62982410.3389/fped.2021.629824 ↗
34. 10.1073/pnas.160807411310.1073/pnas.1608074113 ↗
35. 10.1111/aor.1283210.1111/aor.12832 ↗
36. 10.1111/jth.1436010.1111/jth.14360 ↗
37. 10.1186/s13054-021-03581-x10.1186/s13054-021-03581-x ↗
38. 10.1056/NEJMra210409110.1056/NEJMra2104091 ↗
39. 10.1016/j.athoracsur.2006.11.05110.1016/j.athoracsur.2006.11.051 ↗
40. 10.1126/scitranslmed.300680410.1126/scitranslmed.3006804 ↗
41. 10.1016/j.athoracsur.2019.08.04010.1016/j.athoracsur.2019.08.040 ↗
42. 10.1021/acsbiomaterials.1c0075810.1021/acsbiomaterials.1c00758 ↗
43. 10.1186/s12959-023-00452-z10.1186/s12959-023-00452-z ↗
44. 10.1002/adfm.20110170710.1002/adfm.201101707 ↗
45. 10.1161/STROKEAHA.115.01106310.1161/STROKEAHA.115.011063 ↗
46. 10.1021/bm301143d10.1021/bm301143d ↗
47. 10.1039/C1SM06513K10.1039/C1SM06513K ↗
48. 10.1038/nnano.2012.8410.1038/nnano.2012.84 ↗
49. 10.1002/adhm.20200219610.1002/adhm.202002196 ↗
50. 10.1001/jamaneurol.2014.288610.1001/jamaneurol.2014.2886 ↗
51. 10.1093/cvr/cvt10210.1093/cvr/cvt102 ↗
52. 10.1126/science.121781510.1126/science.1217815 ↗
53. 10.1016/j.jbiomech.2010.07.01110.1016/j.jbiomech.2010.07.011 ↗
54. 10.3389/fcvm.2023.108354710.3389/fcvm.2023.1083547 ↗
55. 10.1002/adhm.20190003610.1002/adhm.201900036 ↗
56. 10.3389/fphys.2020.0086110.3389/fphys.2020.00861 ↗
57. 10.1152/physrev.00047.200910.1152/physrev.00047.2009 ↗
58. 10.1038/nprot.2014.09110.1038/nprot.2014.091 ↗
59. 10.1016/j.atherosclerosis.2006.11.01910.1016/j.atherosclerosis.2006.11.019 ↗
60. 10.1146/annurev.fluid.29.1.39910.1146/annurev.fluid.29.1.399 ↗
61. 10.1085/jgp.69.4.44910.1085/jgp.69.4.449 ↗
62. 10.1038/s41598-018-32247-y10.1038/s41598-018-32247-y ↗
63. 10.1186/s13054-019-2622-310.1186/s13054-019-2622-3 ↗
64. 10.1016/j.nano.2021.10240510.1016/j.nano.2021.102405 ↗
65. 10.1016/j.jvs.2014.12.05010.1016/j.jvs.2014.12.050 ↗
66. 10.3389/fcvm.2022.83527010.3389/fcvm.2022.835270 ↗
67. 10.1016/j.ijcha.2014.10.00410.1016/j.ijcha.2014.10.004 ↗
68. 10.1186/1475-925X-5-4010.1186/1475-925X-5-40 ↗
69. Otto C. M. · Mass Medical Soc. · 2000 · 343 · 652
70. 10.1007/s12195-020-00631-210.1007/s12195-020-00631-2 ↗
71. 10.1157/1308364110.1157/13083641 ↗
72. 10.1046/j.1523-1755.1998.06720.x10.1046/j.1523-1755.1998.06720.x ↗
73. 10.1186/s13054-019-2622-310.1186/s13054-019-2622-3 ↗
74. 10.1097/00002480-200209000-0001910.1097/00002480-200209000-00019 ↗
75. 10.1111/j.1525-1594.2011.01416.x10.1111/j.1525-1594.2011.01416.x ↗
76. 10.1161/CIRCULATIONAHA.120.04553610.1161/CIRCULATIONAHA.120.045536 ↗
77. 10.1016/j.athoracsur.2015.10.06910.1016/j.athoracsur.2015.10.069 ↗
78. 10.3390/fluids710032510.3390/fluids7100325 ↗
79. 10.1002/adma.20180237310.1002/adma.201802373 ↗
80. 10.1016/j.colsurfb.2019.11071810.1016/j.colsurfb.2019.110718 ↗
81. Samuel S. P. · Int. J. Nanomed. · 2012 · 7 · 2943
82. 10.1039/C9SM01820D10.1039/C9SM01820D ↗
83. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
84. 10.1002/adhm.20220115110.1002/adhm.202201151 ↗
85. 10.1016/j.jcis.2004.12.01910.1016/j.jcis.2004.12.019 ↗
86. 10.1021/acs.nanolett.0c0049510.1021/acs.nanolett.0c00495 ↗
87. 10.1111/jth.1366610.1111/jth.13666 ↗
88. 10.1002/smll.20160032810.1002/smll.201600328 ↗
89. 10.1021/am405992t10.1021/am405992t ↗
90. 10.1021/ac050312q10.1021/ac050312q ↗
91. 10.1002/adfm.20210047810.1002/adfm.202100478 ↗
92. 10.1097/MAT.000000000000172310.1097/MAT.0000000000001723 ↗
93. 10.3389/fphar.2020.0112410.3389/fphar.2020.01124 ↗
94. 10.1053/j.jvca.2021.10.02610.1053/j.jvca.2021.10.026 ↗
95. 10.1016/j.healun.2021.01.212410.1016/j.healun.2021.01.2124 ↗
96. 10.1513/AnnalsATS.202102-127RL10.1513/AnnalsATS.202102-127RL ↗
97. 10.1007/s00134-021-06593-x10.1007/s00134-021-06593-x ↗
98. 10.1111/jth.1294710.1111/jth.12947 ↗
99. 10.2174/13816121079451925510.2174/138161210794519255 ↗
100. 10.1038/s41573-021-00284-410.1038/s41573-021-00284-4 ↗